Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
07 2020
Historique:
received: 14 12 2018
revised: 17 03 2020
accepted: 16 04 2020
pubmed: 20 5 2020
medline: 20 7 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

Currently, microsatellite instability (MSI) detection is limited to tissue samples with sufficient tumor content. Detection of MSI from blood has been explored but confounded by low sensitivity due to limited circulating tumor DNA (ctDNA). We developed a next-generation sequencing-based algorithm, blood MSI signature enrichment analysis, to detect MSI from blood. Blood MSI signature enrichment analysis development involved three major steps. First, marker sites that can effectively distinguish high MSI (MSI-H) from microsatellite stable tumors were extracted. Second, MSI signature enrichment analysis was performed based on hypergeometric probability, under the null hypothesis that plasma samples have similar MSI-H and microsatellite stable read coverage patterns for particular marker sites as the white blood cells from the training data set. Finally, enrichment scores of marker sites were normalized, and all markers were collectively considered to determine the MSI status of a plasma sample. In vitro dilution experiments with cell lines and in silico simulation experiments based on mixtures of MSI-H plasma and paired white blood cell DNA demonstrated 98% sensitivity and 100% specificity at a minimum of 1% ctDNA and 91.8% sensitivity and 100% specificity with 0.4% ctDNA. An independent validation cohort of 87 colorectal cancer patients with orthogonal confirmation of MSI status of tissues confirmed performance, achieving 94.1% sensitivity (16/17) and 100% specificity (27/27) for samples with ctDNA >0.4%.

Identifiants

pubmed: 32428677
pii: S1525-1578(20)30324-X
doi: 10.1016/j.jmoldx.2020.04.210
pii:
doi:

Substances chimiques

Circulating Tumor DNA 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

860-870

Informations de copyright

Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Zhenghao Cai (Z)

Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China; Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China.

Zhenxin Wang (Z)

Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.

Chenglin Liu (C)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Dongtao Shi (D)

Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.

Dapeng Li (D)

Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.

Minhua Zheng (M)

Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China; Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China.

Han Han-Zhang (H)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Analyn Lizaso (A)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Jianxing Xiang (J)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Juan Lv (J)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Wenjun Wu (W)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Zhihong Zhang (Z)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Zhou Zhang (Z)

Burning Rock Biotech, Guangzhou, People's Republic of China.

Fei Yuan (F)

Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China.

Songbing He (S)

Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. Electronic address: hesongbing1979@suda.edu.cn.

Jing Sun (J)

Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China; Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China. Electronic address: sj11788@rjh.com.cn.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH